Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 ...

IMUNON, Inc. (IMNN) said on Wednesday its first patient has been dosed with the firm’s lead candidate, IMNN-001, as part of a ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update First Patient Dosed in Phase 3 OVATION 3 Trial On July 30, 2025, ...

Imunon, Inc. (($IMNN)) has held its Q2 earnings call. Read on for the main highlights of the call. The recent earnings call for Imunon, Inc.

Shares of IMUNON are trading higher Wednesday morning. The company announced a clinical milestone for its lead drug candidate ...

The current quarter introduced the 15% onetime stock dividend and confirmed accelerated site activation for OVATION 3, compared to the previous quarter's focus on initial site readiness and ...

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study ...

(Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the first patient has been dosed in the pivotal Phase 3 OVATION 3 Study ...

IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Analysts expect Imunon to report an earnings per share (EPS) of $-3.09. The market awaits Imunon's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the ...

IMUNON, Inc. announced a successful Type C Chemistry, Manufacturing, and Controls (CMC) meeting with the FDA, which aligns their production strategy for IMNN-001, a DNA-mediated immunotherapy ...

IMUNON previously reported positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m 2 administered intraperitoneally weekly) plus neoadjuvant and ...